The cost-effectiveness of HPV vaccination in addition to screening
| Autor: | Maarten J. Postma, Tjalke A Westra, Bob Wilffert, Jos Luttjeboer, Toos Daemen, Auliya A. Suwantika, Jan Wilschut, Didik Setiawan, Jarir Atthobari |
|---|---|
| Přispěvatelé: | Microbes in Health and Disease (MHD), Targeted Gynaecologic Oncology (TARGON), Methods in Medicines evaluation & Outcomes research (M2O), Reproductive Origins of Adult Health and Disease (ROAHD), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Value, Affordability and Sustainability (VALUE) |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
HPV16/18 VACCINATION Cost effectiveness cervical cancer Cost-Benefit Analysis Immunology CLINICAL BENEFIT cervical cancer screening Uterine Cervical Neoplasms HPV vaccines ECONOMIC-EVALUATION Environmental health Drug Discovery medicine Humans Mass Screening Papillomavirus Vaccines cost-effectiveness OF-STUDY ANALYSIS Netherlands Pharmacology Cervical cancer Cancer prevention Cervical screening HPV vaccination PREVENT CERVICAL-CANCER business.industry Papillomavirus Infections Vaccination Hpv vaccination The Netherlands HUMAN-PAPILLOMAVIRUS VACCINATION medicine.disease HPV-16/18 AS04-ADJUVANTED VACCINE QUADRIVALENT VACCINE CROSS-PROTECTION Economic evaluation Molecular Medicine Female business BLIND PATRICIA TRIAL |
| Zdroj: | Expert review of vaccines, 14(4), 589-604. TAYLOR & FRANCIS LTD |
| ISSN: | 1744-8395 1476-0584 |
| Popis: | Addition of the HPV vaccine to available cytological screening has been proposed to increase HPV-related cancer prevention. A comprehensive review on this combined strategy implemented in the Netherlands is lacking. For this review, we therefore analyzed all relevant studies on cost-effectiveness of HPV vaccines in combination with cervical screening in the Netherlands. Most of the studies agree that vaccination in pre-sexual-activity periods of life is cost-effective. Based on published sensitivity analyses, the incremental cost-effectiveness ratio was found to be mainly driven by vaccine cost and discount rates. Fewer vaccine doses, inclusion of additional benefits of these vaccines to prevent HPV-related non-cervical cancers and vaccination of males to further reduce the burden of HPV-induced cancers are three relevant options suggested to be investigated in upcoming economic evaluations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|